Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02831751 · ClinicalTrials.gov registry record · Phase 2
Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults
A Phase 2 study, sponsored by Medicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,001
- Enrollment target
NCT02831751: Completed Phase 2 study, sponsored by Medicago.
NCT02831751 is a Phase 2 study that has completed, run by Medicago. The registered enrollment target is 1,001 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (653% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02831751, a Phase 2 study, has completed, sponsored by Medicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,001 participants
- Enrollment target
Study Summary
This Phase 2 Quadrivalent VLP Vaccine study is intended to replicate and extend the immunogenicity and safety results obtained in earlier Phase 1-2 and Phase 2 studies. The study is being conducted to evaluate that the immunogenicity profile of the Quadrivalent VLP Vaccine meets the US Center for Biologics Evaluation and Research (CBER) licensure criteria and to evaluate if the immunogenicity and the safety profile of the Quadrivalent VLP Vaccine is acceptable and comparable to that of the FluLaval® Tetra and Fluzone® High-Dose (HD). The study will also help to define the optimal dose in this population, establish potential competitive advantages, and support the design of future studies.
Primary Outcome
Immunogenicity will be assessed by the geometric mean titers (GMT)
Interventions
- BIOLOGICAL 30 µg/strain of Quadrivalent VLP Vaccine
- BIOLOGICAL 60 µg/strain of Quadrivalent VLP Vaccine
- BIOLOGICAL FluLaval® Tetra (15 µg/strain)
- BIOLOGICAL Fluzone® High-Dose (60 µg/strain)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,001 participants |
| Start Date | 2016-04 |
| Est. Completion | 2017-01 |
| Phase | Phase 2 |
What the finished NCT02831751 record still lists
NCT02831751 is an interventional study that assigns participants to a tested intervention. Its 1,001 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (653% higher).
The record links to 0 conditions, and to 4 interventions - of which 30 µg/strain of Quadrivalent VLP Vaccine is the first listed.
NCT02831751 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02831751 about?
NCT02831751 is a clinical study titled "Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults". This Phase 2 Quadrivalent VLP Vaccine study is intended to replicate and extend the immunogenicity and safety results obtained in earlier Phase 1-2 and Phase 2 studies. The study is being conducted to evaluate that the immunogenicity profile of the Quadrivalent VLP Vaccine meets the US Center for Bi...
What is the current status of trial NCT02831751?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,001 participants. The study started on 2016-04. Estimated completion is 2017-01.
What interventions are being tested in trial NCT02831751?
The interventions under investigation include: 30 µg/strain of Quadrivalent VLP Vaccine (BIOLOGICAL), 60 µg/strain of Quadrivalent VLP Vaccine (BIOLOGICAL), FluLaval® Tetra (15 µg/strain) (BIOLOGICAL), Fluzone® High-Dose (60 µg/strain) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02831751?
This trial is sponsored by Medicago, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02831751's enrollment target sits among peer trials
1,001 25th of 2000 higher than 1,976 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06207864 · 1,001 participants · NA
Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia